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Knockdown of E2F2 Inhibits Tumorigenicity, but
Preserves Stemness of Human Embryonic Stem Cells
Daniela Emi Suzuki,1,2 Adriana Miti Nakahata,3 and Oswaldo Keith Okamoto2
Tumorigenicity of human pluripotent stem cells is a major threat limiting their application in cell therapy
protocols. It remains unclear, however, whether suppression of tumorigenic potential can be achieved without
critically affecting pluripotency. A previous study has identified hyperexpressed genes in cancer stem cells,
among which is E2F2, a gene involved in malignant transformation and stem cell self-renewal. Here we tested
whether E2F2 knockdown would affect the proliferative capacity and tumorigenicity of human embryonic stem
cells (hESC). Transient E2F2 silencing in hESC significantly inhibited expression of the proto-oncogenes BMI1
and HMGA1, in addition to proliferation of hESC, indicated by a higher proportion of cells in G1, fewer cells in
G2/M phase, and a reduced capacity to generate hESC colonies in vitro. Nonetheless, E2F2-silenced cells kept
expression of typical pluripotency markers and displayed differentiation capacity in vitro. More importantly,
E2F2 knockdown in hESC significantly inhibited tumor growth in vivo, which was considerably smaller than
tumors generated from control hESC, although displaying typical teratoma traits, a major indicator of plur-
ipotency retention in E2F2-silenced cells. These results suggest that E2F2 knockdown can inhibit hESC
proliferation and tumorigenicity without significantly harming stemness, providing a rationale to future pro-
tocols aiming at minimizing risks related to therapeutic application of cells and/or products derived from human
pluripotent cells.
Introduction
The undoubted contribution that human embryonicstem cells (hESC) have made to advancements in stem
cell research since the derivation of the first ESC lines more
than a decade ago [1], consolidate them as natural models to
study cell differentiation. ESC are also valuable in the study
of tumorigenesis, due to their well-known capacity to form
teratomas. Indeed, pluripotency and tumorigenicity have
long been shown to be coupled processes. One of the early
evidences came from experiments in which murine terato-
carcinoma cells introduced in 6-day-old embryos were found
capable of differentiating into somatic and germline cells,
contributing to tissue development in the offspring [2]. More
recently, different groups have shown that teratoma forma-
tion capability is an ancillary property acquired after repro-
gramming of differentiated somatic cells to a pluripotent state
[3,4]. In fact, generation of teratoma is now part of routine
characterization assays to evaluate the quality of induced
pluripotent stem (iPS) cell preparations.
In the general rush toward implementing cell therapy for
patients with unmet medical needs, acute and long-term
safety issues cannot be ignored and should be properly ad-
dressed. In that sense, tumor formation persists as a major
threat limiting potential therapeutic application of differen-
tiated cells derived from pluripotent ones. Generation of iPS
cells itself also involve potential oncogenic hazards [5].
However, since both pluripotency and tumorigenicity are
related processes sharing common regulatory pathways [6],
lowering the tumorigenic potential of pluripotent cells may
not be a straightforward procedure.
Ideally, mechanisms inhibiting tumorigenesis should
avoid permanent or uncontrolled modification of the ge-
nome and should not significantly affect pluripotency, al-
though the latter issue remains to be clarified. Embryonic
stem cells are known to rapidly proliferate [7] and setting
proliferation rates of somatic cells to a similar pace, by
accelerating cell cycling, improves reprogramming [8,9].
Nonetheless, regulation of ESC proliferation differs from
that of somatic cells, involving particular cell cycle pro-
teins [10], which reveals a more complex interplay with
pluripotency.
Previous studies have shown that omission of c-MYC
expression [11] or additional copies of p53 or Ink4a/ARF
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[12] do not disturb pluripotency induction of mouse fibro-
blasts. Reducing the cyclin A1 protein to correct levels has
been reported to reduce tumorigenicity of mouse iPS cells,
while improving reprogramming to ground state plur-
ipotency [13]. Taken together, these observations suggest
that modulation of pathways regulated by classic proto-
oncogenes and tumor suppressors, as well as cell cycle
regulators, might be a feasible strategy toward reducing
tumorigenicity of hESC, with limited impact on stemness.
In this study, we asked whether knockdown of the E2F2
gene encoding a transcription factor with important func-
tions in the control of embryonic development, cell cycle,
and apoptosis [14], would inhibit the tumorigenicity of
hESC. The canonical E2F control of cell cycle progression,
DNA replication, checkpoint control, apoptosis, DNA
damage repair, and cell differentiation involves interaction
with the tumor suppressor Rb. Such Rb/E2F network is
often deregulated in cancer [15]. E2F also induces the
transcription of oncogenes typically associated with poor
prognosis, such as HMGA1, BMI1, and MELK [16–18]. The
genes, BMI1 and MELK, in particular, are essential for self-
renewal of normal and neoplastic stem cells [19–21].
Function of E2F2, however, is less characterized relative to
other members of the E2F family. In astrocytomas, E2F2
directly regulates Bcl-2 gene expression, increasing cell
resistance to apoptosis [22], and aberrant E2F2 expression
in stem-like cells positively correlates with tumor malig-
nancy [23].
In this study, we found that E2F2 knockdown in hESC
caused a significant decrease in HMGA1 and BMI1 ex-
pression, followed by a significant reduction in cell prolif-
eration and tumorigenicity, without significantly affecting
pluripotency.
Materials and Methods
Cell culture
The hESC line H9 was kindly provided by LANCE
(Laborato´rio Nacional de Ce´lulas-tronco Embriona´rias–
Universidade Federal do Rio de Janeiro, Brazil). Cells were
cultured under a feeder-free system using Matrigel-coated
plates (BD Bioscience) with conditioned cell growth media
(mTeSR–StemCell Technology), at 37C, 5% CO2, and
90%–95% humidity, retaining their undifferentiated state.
Growth media were changed daily and culture passage was
performed when cells reached 80% confluence, by enzy-
matic dissociation with Accutase (StemCell Technology).
E2F2 knockdown
Plasmids carrying shRNA against E2F2 (shE2F2) (Sur-
eSilencing shRNA Plasmids; SABiosciences) were
transfected into hESC using Lipofectamine RNAiMAX
(Life Technologies) according to the manufacturer’s in-
structions. Briefly, hESC were seeded in a six-well plate
(1 · 105 cells/well), suspended in 0.5 mg shE2F2/lipofecta-
mine solution, and incubated at room temperature for
20min. Afterward, a conditioned medium was added to the
suspension and cells were transferred into a Matrigel-coated
plate for overnight cultivation. In the second day of trans-
fection, the medium was replaced with a fresh conditioned
medium. Another round of transfection was performed (48 h
after the first transfection), following the same procedure
described. Cells transfected with nonspecific DNA were
used as negative control (CT - ). Positive control cells were
treated with Lipofectamine RNAiMAX, as the other ex-
perimental groups, but received no plasmids. After 24 h of
the second transfection, cells were selected by cultivation
with 250 mg/mL neomycin (G418–Life Technologies) for 3
days, with daily medium changing. Transfected hESC col-
onies were maintained in the conditioned medium until their
use in downstream experiments.
Quantification of gene expression by real-time PCR
Total RNA was extracted from hESCs using the RNeasy
Mini Kit (Qiagen, Inc.), according to the manufacturer’s
instructions. The RNA concentration was estimated by ab-
sorbance at 260 with NANO DROP (Qiagen, Inc.). The
A260/A280 ratios in the range of 1.8–2.0 were considered
satisfactory for purity standards. Denaturing agarose gel
electrophoresis was used to assess the RNA quality. cDNA
was synthesized from 1 mg of total RNA using the oligo-dT
primer and 200U of Superscript II Reverse Transcriptase
(Life Technologies). Quantitative PCR was performed in a
7500 Real-Time PCR System Thermal Cycler (Applied
Biosystems) by the SYBR-Green approach (Platinum SYBR
Green qPCR SuperMix-UDG; Life Technologies). Ampli-
fication specificity was assessed by dissociation curve
analysis. Expression of the housekeeping gene Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was used as
endogenous control. Quantification was based on linear re-
gression analysis from standard curves determined for each
gene analyzed, with amplification efficiencies ranging from
90% to 100%. The cDNA samples were subjected to PCR
amplification using specific primers designed in different
exons and annealing temperature varying from 58C to 68C
(Supplementary Table S1; Supplementary Data are available
online at www.liebertpub.com/scd). Negative control RT-
PCR reactions were carried out under the same conditions
without addition of cDNA. Reactions were performed in
triplicate.
Cell cycle and colony assays
The hESC cycling activity was analyzed using the Guava
Cell Cycle Reagent Kit (Millipore—Guava Technologies)
according to the manufacturer’s procedure. Briefly, 1 · 105
cells per sample were harvested and dissociated until single
cell suspension for staining. Cells were then fixed in cold
70% ethanol at 4C for 24 h, washed in 1 · PBS, and in-
cubated in Guava Cell Cycle Reagent at room temperature
for 30min, shielded from light. Samples were analyzed in
the Guava EasyCyte 5HT Flow Cytometer (Millipore—
Guava Technologies) using GuavaSoft 2.1 software. Pro-
liferation of hESC was also analyzed by the size and
number of cell colonies grown in vitro as previously de-
scribed [24]. Briefly, cells were cultivated under low at-
tachment conditions and alkaline phosphatase-positive
colonies were examined in an Axio Vert.A1 Microscope
(Carl Zeiss) by the AxioVision 4.8.2 software. The number
of colonies was determined according to their sizes 100–
200, 200–500, and 500–1,500 mm. Samples were analyzed
in duplicate.
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Analysis of pluripotency markers
Pluripotency of transfected cells were examined by the
FlowCellect Human ESC Surface Marker (HESCA-1,
SSEA1, and SSEA4) Characterization Kit (Millipore), fol-
lowing the manufacturer’s instructions. Intracellular levels
of the pluripotent factors OCT4 and SOX2 were also de-
termined in permeabilized hESC. Samples were analyzed in
a Guava EasyCyte 5HT Flow Cytometer (Millipore—Guava
Technologies).
In vitro cell differentiation assays
Spontaneous differentiation in vitro was evaluated
through embryoid body (EB) formation. Cells were disso-
ciated until single cells, plated into ultralow adhesion plates
(Corning), and cultured in suspension in an EB medium
consisting of DMEM/F12 +GlutaMax, 15% knockout serum
replacement (KSR), 1% MEM-nonessential amino acids
(NEAA), and 0.1mM b–mercaptoethanol (b-ME) (all from
Gibco Invitrogen) for 7 days. The medium was changed
every other day until complete EB formation, as described
by Fernandes et al. [25]. EBs higher than 200 mm were
counted for statistical analysis. hESCs were also subjected
to neural differentiation according to Baharvand et al. [26].
Cells were cultured for 4–5 days in the absence of feeder
layer (Matrigel) with the conditioned medium (mTeSR).
The generation of neural rosettes was induced with 4 mM
retinoic acid (RA; Sigma-Aldrich) in the differentiation
medium (DMEM/F12 +GlutaMax, 1% NEAA, and 0.1mM
b-ME) with 5% KSR and without bFGF, for 2 weeks.
Neural tube-like structures, obtained in the third week of
differentiation by adding 25 ng/mL bFGF, were selected
manually and plated on 5 mg/mL laminin and 15 mg/mL poly
L-ornithine (both Sigma-Aldrich) precoated culture dishes
(Corning) and cultured in the neurobasal medium supple-
mented with 1% N2 and 2% B27 (all from Gibco Invitro-
gen) for 30 days.
Teratoma assay
Teratoma formation was assessed by subcutaneously in-
jecting 5 · 106 hESC, suspended in 300 mL of Matrigel, into
the right flank of 4- to 8-week-old Balb/C nude mice (n = 9)
[27]. Tumors were measured every other day with a digital
caliper. Animals were sacrificed when tumors reached a
volume of approximately 1,500mm3. Teratomas were
weighed and analyzed by hematoxylin and eosin (HE)
staining. The tumor volume was calculated by the following
formula: volume (mm3) =width diameter2 · length diame-
ter · 0.5. The generation of intracranial tumors was analyzed
by injecting 5 · 106 hESC, suspended in 5 mL DMEM/F12
without KSR, with a high precision microsyringe (model
701RN; Hamilton Co.) into the right striatum at a 0.5 mL/
min rate, using a stereotaxic equipment (Insight, BR). Brain
tissue was evaluated by HE staining 30 days postintracranial
implantation of cells. Animals were kept at 22C–24C,
under a controlled 12-h light–12-h dark cycle, with free
access to food and water. All efforts were made to minimize
FIG. 1. Expression of proto-oncogenes after E2F2 knockdown in human embryonic stem cells (hESC). In addition to
E2F2 (A), a significant decrease in the expression of BMI1 (B) and HMGA (C) proto-oncogenes was also detected, whereas
expression of c-MYC (D), MELK (E), and b-MYB (F) was not affected. Gene expression was quantified 7 days post-
transfection with E2F2 silencing plasmids by real-time PCR, using GAPDH as endogenous control. Data are expressed as
percentage relative to control. **P < 0.01, ***P < 0.001.
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animal suffering, as proposed by the International Ethical
Guideline for Biomedical Research (CIOMS/OMS, 1985)
and the study was approved by the Internal Review Board of
the Federal University of Sa˜o Paulo (CEP No. 2096/08).
Statistical analysis
All experiments used triplicate samples and three inde-
pendent experiments were carried out. Data were analyzed
by ANOVA with the Bonferroni post hoc test. Significance
was established at the P £ 0.05 level. Results are expressed
as mean –SD.
Results
E2F2 knockdown affects expression of selected
proto-oncogenes in hESC
Double transfection of hESC with shRNA plasmids spe-
cifically inhibited E2F2 expression, reaching a silencing
level of about 60% after 7 days of initial transfection
(P < 0.001) (Fig. 1A). A significant reduction in the ex-
pression levels of the E2F targeted proto-oncogenes BMI1
and HMGA was also found in hESC with silenced E2F2,
compared with control cells. Equivalent silencing levels
(40% for BMI1 and 41% for HMGA) were verified for these
two proto-oncogenes after 7 days of initial transfection of
hESC with shE2F2 plasmids (Fig. 1B, C). However, under
the same experimental conditions, expression of other
classical proto-oncogenes in hESC was not affected by the
E2F2 knockdown. As indicated in Fig. 1D–F, expression of
c-MYC, MELK, and b-MYB, the last two genes also known
to be involved in stem cell self-renewal, was not signifi-
cantly changed after 7 days of initial E2F2 silencing.
E2F2 knockdown significantly inhibits hESC
proliferation
Cell cycle analysis of hESC subjected to E2F2 silencing
indicated a lower percentage of cells at both the S (P < 0.01)
and G2/M phases (P < 0.001), as well as a higher amount of
cells at G1 (P < 0.001), compared with control cells (Fig.
2A). To confirm the effects of E2F2 knockdown on cell
proliferation, the amount of hESC colonies developed in
vitro under E2F2 silencing was determined. In agreement
with the previously verified cell cycle inhibition, the ca-
pacity of hESC to generate colonies was significantly af-
fected by the E2F2 knockdown. A reduced amount of hESC
colonies of large (500–1,500 mm) diameter were detected
after 4 and 7 days of growth under E2F2 silencing (Fig. 2B).
Earlier culture periods were not suitable for such evaluation
since most hESC colonies were still underdeveloped (below
200 mm). In some samples, hESC treated with scrambled
shRNA (CT - ) also yielded lower amounts of colonies
compared with positive control cells, mostly after 7 days of
growth, although not achieving overall significantly reduced
levels.
hESC retain stemness despite E2F2 knockdown
In spite of the reduced proliferative activity of hESC
verified upon E2F2 knockdown, under such conditions, no
evident signs of pluripotency loss were found. The propor-
tion of pluripotent cells based on the expression of typical
membrane surface markers (HESCA + /SSEA4 + /SSEA1 -
immunophenotype) was not significantly altered in the
E2F2–silenced group, compared with controls (Fig. 3A).
These results were further confirmed when determining the
intracellular levels of pluripotency factors. Seven days post-
E2F2 knockdown, most hESC were still positive for OCT4
and SOX2 expression (98% and 96% of the total cell pop-
ulation analyzed, respectively), displaying frequency and
signal levels similar to positive control cells (Fig. 3B).
hESC with silenced E2F2 were also capable of forming
EBs, indicating a preserved capacity to spontaneously dif-
ferentiate and form three-dimensional multicellular aggre-
gates in vitro. However, as shown in Fig. 3C, a somewhat
reduced amount of EBs ( ‡ 200mm in diameter) was devel-
oped from hESC kept for 7 days under E2F2 silencing,
compared with controls. This result, nonetheless, is in
agreement with the initial cell proliferation inhibition ob-
served after E2F2 knockdown. When subjected to directed
neural differentiation conditions, control and E2F2-silenced
cells responded in a similar fashion to such stimulus. As
shown in Fig. 4, typical neural rosettes comprising columnar
FIG. 2. E2F2 knockdown significantly inhibits hESC
proliferation. (A) Relative amount of cells in G1, S, and G2/
M phases of the cell cycle at day seven post-transfection
with E2F2 silencing plasmids, determined by flow cytom-
etry. (B) Amount of hESC colonies ( ‡ 500mm) developed
up to 7 days in vitro. hESC (positive control cells, treated
with lipofectamine only); CT (negative control cells, trans-
fected with nonspecific DNA); shE2F2 (cells transfected
with E2F2 silencing plasmids). **P < 0.01; ***P < 0.001.
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progenitor cells were found in the initial differentiation
stage (Fig. 4A–C). A later cell organization into neural
tube-like structures was also observed after bFGF addition
to the medium (Fig. 4D–F). At a later differentiation stage,
numerous processes and fibers grew out from the neural
tube-like structures and some migrating cells could be
visualized in association with these structures (Fig. 4G–I).
The generation of neural rosettes also occurred when
control cells and E2F2-silenced hESC where directly in-
jected into mouse brains (Fig. 4J–L), an indication that the
capacity to respond to in vivo neural differentiation cues
was also maintained.
E2F2 knockdown suppresses tumorigenicity
of hESC
When injected subcutaneously in nude mice, E2F2-
silenced hESC were capable of generating teratomas, a
further indication of stemness retention. Nontheless, tumors
developed from E2F2-silenced hESC grew at a lower pace
compared with tumor growth kinetics from control cells,
reaching significantly smaller volumes 60 days postinjection
(Fig. 5A, B). Mice bearing E2F2-silenced hESC teratomas
were further monitored untill 80 days postinjection, when
tumor volumes were still below 250mm3 and exponential
tumor growth was absent. Conversely, teratomas developed
from control hESC reached similar volumes (250mm3)
within 45 days and were already over 1,500mm3 in volume
at day 60, postinjection.
When excised, teratomas had a mixed consistency dis-
playing solid areas combined with fluid-filled cysts. A
careful histological analysis of teratomas generated from
control and E2F2-silenced cells revealed tissue structures
representing all three germ layers. As shown in Fig. 5C,
various structures could be detected, including gut-like ep-
ithelial tissues (endoderm), muscle, cartilage, and adipose
tissues (mesoderm), as well as neural tissue (ectoderm).
Discussion
The function of the E2F2 transcription factor in tumori-
genesis is poorly characterized, relative to other members of
the E2F family. Studies with mouse models have reported
both tumor suppression and pro-oncogenic activities.
Whereas mice lacking E2F2 (either E2F2 + /- or E2F2- / - )
provide evidence of a haploinsufficient tumor suppressor
function for E2F2 in murine models of lymphomagenesis
[28] and MYC-driven mammary tumors [29], mice over-
expressing E2F2 were reported to develop thymomas [30].
Mouse fibroblasts stably overexpressing E2F2 were also
found highly prone to oncogenic transformation [31].
In human cancers, however, most studies support a pro-
oncogenic role for E2F2. E2F2 has been shown to positively
regulate MYCN transcription in aggressive neuroblastomas
[32] and to induce cell proliferation in breast cancer cells,
under control of the AP-1 transcription factor [33]. High
E2F2 expression has also been associated with poor prog-
nosis. In breast cancer, increased E2F2 expression was
FIG. 3. Pluripotency of hESC is preserved after E2F2 knockdown. (A) Flow cytometry analysis of pluripotent cells based
on expression of typical surface markers HESCA, SSEA4, and SSEA1. Data are expressed as percentage relative to control.
(B) Percentage of cells expressing the intranuclear pluripotency factors OCT4 and SOX2, after 7 days of E2F2 knockdown.
Values detected by flow cytometry were consistent with positive control cells. (C) Generation of embryoid bodies in vitro.
Scale bar: 200 mm. hESC (positive control cells, treated with lipofectamine only); CT (negative control cells, transfected
with nonspecific DNA); shE2F2 (cells transfected with E2F2 silencing plasmids).
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reported to be associated with poor patient survival [34]. In
glioblastoma, E2F2 was found hyperexpressed in CD133 +
tumor cells, and its expression correlated with the tumor
malignancy grade [23].
One evidence linking E2F2 and pluripotency was pro-
vided by a recent study using an ectopic xenograft model of
prostate cancer, where E2F2 silencing by let-7a, a micro-
RNA known to regulate expression of the pluripotent factor
OCT4, caused suppression of tumorigenesis in nude mice
[35]. Another recent study integrating whole trancriptome
and binding site analyzes suggested E2F as a central regu-
lator of self-renewal of both hESC and hIPS cells [36],
through modulation of WNT and FGF pathways. In line
with such evidence, the present study demonstrated for the
first time that E2F2 knockdown significantly inhibits self-
renewal and in vivo tumorigenicity without affecting the
stemness of hESC. In mouse ESC, loss-of-function muta-
tions in the Gpc4 gene encoding a member of the heparin
sulfate proteoglycan superfamily were also reported to re-
duce tumorigenicity. Interestingly, Gpc4 also modulates
WNT and FGF pathways, but the inhibition of tumorige-
nicity may be related to premature cell differentiation since
Gpc4 loss-of-function significantly accelerated ESC differ-
entiation [37]. Similar results were reported for mouse iPS
cells, in which cyclin A1 knockdown-mediated inhibition of
tumorigenicity was partly attributed to an enhanced cell
differentiation capability [13]. In the present study, how-
ever, no significant changes in hESC differentiation were
noted, suggesting differences in the mechanism of tumor
inhibition by E2F2 knockdown.
Since pluripotency and tumorigenicity are linked pro-
cesses controlled by common pathways [6], the mechanism
by which E2F2 inhibits hESC tumorigenicity may involve
regulation of typical proto-oncogenes that do not affect ESC
differentiation pathways. Indeed, the inhibition of BMI and
HMGA1 genes observed after E2F2 knockdown are in
agreement with this notion. However, other target proto-
oncogenes c-MYC, MELK, and b-MYB, were not affected by
the E2F2 knockdown, indicating that such mechanism is all
but ordinary.
Interestingly, in the ESC context, c-MYC, MELK, and b-
MYB proteins are important for cell functionality. High
FIG. 4. E2F2-silenced hESC respond to directed differentiation cues. Cultures of hESC subjected to neural differentiation
stimuli in vitro displayed rosette (A–C) and neural tube-like structures (D–F), despite E2F2 knockdown. Cells with neuropro-
genitor morphology, with evident neural processes and fibers (G–I)were also observable in all cultures.When injected into nude
micebrains, hESCgenerated tumors enriched inneural rosettes. hESC(positive control cells, treatedwith lipofectamine only);CT
(negative control cells, transfected with nonspecific DNA); shE2F2 (cells transfected with E2F2 silencing plasmids). Scale bars:
100mm (A–C), 50mm (D–F), 50mm (G–I), 100mm (J–L). Color images available online at www.liebertpub.com/scd
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levels of c-MYC have been implicated in the maintenance
of ESC fitness at the onset of differentiation [38]. Similarly,
MELK (maternal embryonic leucine zipper kinase), a
member of the Snf1/AMPK family of serine/threonine ki-
nases, is involved in the early and late stages of embryonic
development, where it regulates the germ cell line [39] as
well as neural differentiation, the latter action also involving
the participation of b-MYB [40]. Low levels of b-MYB, on
the other hand, have been reported to induce aneuploidy and
differentiation-associated cell death in murine ESC [41]. EB
and teratoma formation as well as full ectodermic, meso-
dermic, and endodermic differentiation capacity were de-
tected in E2F2-silenced hESC, indicating that they remained
functional despite the interference in gene expression. The
preservation of c-MYC, MELK, and b-MYB expression after
E2F2 knockdown in hESC might explain, at least in part,
the absence of significant inhibition of pluripotency and
differentiation capability found in this study.
Lower levels of E2F factors may also increase the amount
of free Rb, favoring its interaction with other protein part-
ners such as Rb binding proteins (RBBPs). Interestingly,
RBBPs bound to Rb have been detected in hESC and im-
plicated in the maintenance of their pluripotency [42]. In
fact, proper cellular levels of certain cell cycle proteins,
including cyclin A1 and Rem2 GTPase, have been reported
relevant for achieving and sustaining pluripotency [8,13].
In addition to cell proliferation, E2F2 may also regulate
genes affecting other hallmarks of cancer in ESC, such as
cell survival and energy/metabolism. Indeed, in vivo ex-
periments with E2F1-3 knockout mice showed that E2F1-
3 function as transcriptional activators necessary for ESC
survival. In their transit-amplifying cell progeny, E2F1-3
optimally activate expression of E2F responsive targets,
inducing ectopic cell divisions [43]. In silico analyses
have also indicated that E2F directly targets metabolic
network/energy generation pathways driving self-renewal
of human pluripotent stem cells [36]. All these mecha-
nisms may contribute to the E2F2-mediated effects on
hESC tumorigenicity and further studies shall help eluci-
date this question.
In sum, our findings suggest a role for E2F2 in regulating
hESC self-renewal and tumorigenicity. The reported effects
FIG. 5. E2F2 knockdown
inhibits tumorigenicity of
hESC. (A) Time course of ter-
atoma development after sub-
cutaneous injection of hESC in
nude mice. (B) Representative
images of tumors resected 60
days postinjection. (C) Histo-
logical analysis of teratomas
based on hematoxylin and eo-
sin staining, displaying tissue
structures of all three germ
layers (a–c), endoderm; (d–f),
mesoderm; (g–i), ectoderm.
Scale bar: 100mm. hESC (pos-
itive control cells, treated with
lipofectamine only); CT (neg-
ative control cells, transfected
with nonspecific DNA);
shE2F2 (cells transfected with
E2F2 silencing plasmids).
Color images available online
at www.liebertpub.com/scd
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upon E2F2 knockdown provide a rationale for inhibition of
hESC tumorigenicity, with limited effects on pluripotency
and differentiation capacity. Envisioned therapeutic appli-
cations of specialized cells generated from pluripotent cells
will likely require some degree of in vitro cell manipulation
following regulatory guidelines, before administration into
patients. In such procedures, transient and specific silencing
of E2F2 gene or use of small molecule inhibitors of E2F2
could restrain proliferation of partially differentiated cells
and the undesirable occurrence of tumors. Further devel-
opments of this strategy may help circumvent safety issues
concerning future therapeutic application of cells and/or
products derived from human pluripotent cells.
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